APA

Alvarenga D. L. R., Silva A. H. D. S., Fiuza J. A., Gaze S. T., de Oliveira J. G., Oliveira R. C., Calzavara-Silva C. E., Pascoal-Xavier M. A. & Alves É. A. R. (20181012). HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. : International immunopharmacology.

Chicago

Alvarenga Daniele Luísa Ribeiro, Silva Amanda Helen Dos Santos, Fiuza Jacqueline Araújo, Gaze Soraya Torres, de Oliveira Jaquelline Germano, Oliveira Rodrigo Corrêa, Calzavara-Silva Carlos Eduardo, Pascoal-Xavier Marcelo Antônio and Alves Érica Alessandra Rocha. 20181012. HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. : International immunopharmacology.

Harvard

Alvarenga D. L. R., Silva A. H. D. S., Fiuza J. A., Gaze S. T., de Oliveira J. G., Oliveira R. C., Calzavara-Silva C. E., Pascoal-Xavier M. A. and Alves É. A. R. (20181012). HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. : International immunopharmacology.

MLA

Alvarenga Daniele Luísa Ribeiro, Silva Amanda Helen Dos Santos, Fiuza Jacqueline Araújo, Gaze Soraya Torres, de Oliveira Jaquelline Germano, Oliveira Rodrigo Corrêa, Calzavara-Silva Carlos Eduardo, Pascoal-Xavier Marcelo Antônio and Alves Érica Alessandra Rocha. HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. : International immunopharmacology. 20181012.